 RespireRx Pharmaceuticals OTCQB:RSPI Inc has noted the publication of a paper detailing the companys newest candidate D5-KRM-II-81, which is a so-called GABAkine - a type of medicine which enhances the inhibitory neurotransmitter in the brain. This latest asset is a structurally related analog to KRM-II-81, which, as previously reported, RespireRXs EndeavourRx business unit is advancing for the treatment of epilepsy and chronic pain. 